Why the study?
Does therapy adjustment based on platelet function monitoring reduce the incidence of cardiac ischaemic events?
Does therapy adjustment based on platelet function monitoring reduce the incidence of cardiac ischaemic events?
Tailored anti-platelet therapy based on platelet function monitoring does not reduce cardiac ischemic events, which may be partly due to critical issues in the design of the trials testing this strategy.
No takes yet. Share an insight, caveat, or question.
Platelet function monitoring-guided adjustments should not enter clinical practice; leaves open whether refined trial designs could alter this conclusion.
Siller‐Matula et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: